Mostrar el registro sencillo del ítem
dc.contributor.author | Rodríguez-Izquierdo, Ignacio | |
dc.contributor.author | Sepulveda-Crespo, Daniel | |
dc.contributor.author | Lasso, Jose María | |
dc.contributor.author | Resino, Salvador | |
dc.contributor.author | Muñoz-Fernández, María Ángeles | |
dc.date.accessioned | 2022-05-26T11:46:43Z | |
dc.date.available | 2022-05-26T11:46:43Z | |
dc.date.issued | 2022-05 | |
dc.identifier.citation | Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 May;14(3):e1774. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14552 | |
dc.description.abstract | Although a wide variety of topical microbicides provide promising in vitro and in vivo efficacy, most of them failed to prevent sexual transmission of human immunodeficiency virus type 1 (HIV-1) in human clinical trials. In vitro, ex vivo, and in vivo models must be optimized, considering the knowledge acquired from unsuccessful and successful clinical trials to improve the current gaps and the preclinical development protocols. To date, dendrimers are the only nanotool that has advanced to human clinical trials as topical microbicides to prevent HIV-1 transmission. This fact demonstrates the importance and the potential of these molecules as microbicides. Polyanionic dendrimers are highly branched nanocompounds with potent activity against HIV-1 that disturb HIV-1 entry. Herein, the most significant advancements in topical microbicide development, trying to mimic the real-life conditions as closely as possible, are discussed. This review also provides the preclinical assays that anionic dendrimers have passed as microbicides because they can improve current antiviral treatments' efficacy. | es_ES |
dc.description.sponsorship | This work has been (partially) funded by the RD16/0025/0019 projects as part of Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica (2013–2016) and cofinanced by Instituto de Salud Carlos III (ISCIII) and Fondo Europeo de Desarrollo Regional (FEDER), RETIC PT17/0015/0042, Fondo de Investigacion Sanitaria (FIS) (grant no. PI16/01863) and EPIICAL project. COST CA17140 Cancer Nanomedicine-“From the Bench to Bedside.” This work has also been supported by the Ministry of Economy and Competitiveness #CGL2013-40564-R and Gordon and Betty Moore Foundation grant no. 5334. This work was also funded by research grants from ISCIII (grant numbers PI20CIII/00004, and RD16CIII/0002/0002) to Salvador Resino. The study was also funded by the Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CB21/13/00044). DS-C is a “Sara Borrell” researcher from ISCIII (grant no. CD20CIII/00001). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | HIV-1 | es_ES |
dc.subject | Acceptability | es_ES |
dc.subject | Dendrimer | es_ES |
dc.subject | Preclinical steps | es_ES |
dc.subject | Regulation | es_ES |
dc.subject | Vaginal microbicide | es_ES |
dc.title | Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 35018739 | es_ES |
dc.format.volume | 14 | es_ES |
dc.format.number | 3 | es_ES |
dc.format.page | e1774 | es_ES |
dc.identifier.doi | 10.1002/wnan.1774 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Plan Nacional de I+D+i (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | Gordon and Betty Moore Foundation | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERINFEC (Enfermedades Infecciosas) | es_ES |
dc.contributor.funder | Unión Europea. European Cooperation in Science and Technology (COST) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1939-0041 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1002/wnan.1774 | es_ES |
dc.identifier.journal | Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/CA17140 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//RD16%2F0025%2F0019/ES/RED ESPAÑOLA DE INVESTIGACIÓN EN SIDA (RIS)/ | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/MINECO//CGL2013-40564-R/ES/GENOMICA DE VIRUS INDIVIDUALES. UNA NUEVA VISION PARA EXPLORAR LA VIRIOSFERA NO CULTIVADA: DEL ECOSISTEMA AL HOMBRE/ | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/null/PLATAFORMAS DE APOYO A LA INVESTIGACION EN CIENCIAS Y TECNOLOGIAS DE LA SALUD (2017)/PT17/0015/0042 | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI20-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2020)/PI20CIII/00004 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RD16CIII/0002/0002 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CB21/13/00044 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CD20CIII/00001 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PI16/01863 | es_ES |